Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL)
Armand, P. Zinzani, P. L. L. Lee, H. J. Johnson, N. Brice, P. Radford, John A Ribrag, V. Molin, D. Vassilakopoulos, T. P. Tomita, A.
Armand, P.
Zinzani, P. L. L.
Lee, H. J.
Johnson, N.
Brice, P.
Radford, John A
Ribrag, V.
Molin, D.
Vassilakopoulos, T. P.
Tomita, A.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Armand P, Zinzani PLL, Lee HJ, Johnson N, Brice P, Radford J, et al. Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398805094.